First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study

¹Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.;
²Division of Surgical Intensive Care Unit, Department of Intensive Care, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.;
³Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.;
⁴Department of Medicine and Nursing, Hungkuang University, Taichung, Taiwan, R.O.C.;
⁵Institute of Biomedical Science, National Chung Hsing University, Taichung, Taiwan, R.O.C.;
⁶Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan, R.O.C.;
⁷Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.

Correspondence to: Cheng-Kuang Yang, MD, 1650, Sec 4, Taiwan Blvd, Taichung 40700, Taiwan, R.O.C. Tel: +886 423592525 ext. 5120, e-mail: gu5121{at}vghtc.gov.tw